Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.3, and our video podcast, CANCER BUZZ TV.
 

Share

    


Home / Blurb / Discussion Detail

FDA Approves Pembrolizumab + Chemotherapy for TNBC

On November 13, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Keytruda® (pembrolizumab) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test.

Read the FDA announcement.

Read the Merck press release.

Posted 11/16/2020